Timolol 0.5% Ophthalmic Solution — Competitive Intelligence Brief

Timolol 0.5% Ophthalmic Solution (Timolol 0.5% Ophthalmic Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic antagonist. Area: Ophthalmology.

marketed Beta-adrenergic antagonist Beta-1 and beta-2 adrenergic receptors Ophthalmology Small molecule

Target snapshot

Timolol 0.5% Ophthalmic Solution (Timolol 0.5% Ophthalmic Solution) — University of California, Davis. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Timolol 0.5% Ophthalmic Solution TARGET	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
betablocker titration	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Combigan Two Times Daily (BID)	Combigan Two Times Daily (BID)	Cornerstone Health Care, PA	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker	Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors
Topical timolol maleate	Topical timolol maleate	Unity Health Toronto	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	Keith G. LeBlanc, Jr, MD	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
Hydrocortisone/ Placebo and Propranolol	Hydrocortisone/ Placebo and Propranolol	University of Dundee	marketed	Glucocorticoid + Beta-blocker combination	Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic antagonist class)

1. Ain Shams University · 1 drug in this class
2. Policlinico Casilino ASL RMB · 1 drug in this class
3. Unity Health Toronto · 1 drug in this class
4. University of California, Davis · 1 drug in this class